Beyond anticoagulation: Roles for heparin in the vasculature

Heparin: Properties, Uses and Side Effects

Volumn , Issue , 2012, Pages 59-81

  Slee, Joshua B ^a   Pugh, Raymond ^a   Lowe Krentz, Linda J ^a  

^a LEHIGH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84891986274     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (100)

1. Alexopoulou, AN, Multhaupt, HA, and Couchman JR. Syndecans in wound healing, inflammation, and vascular biology. Int. J Biochem Cell Biol. 2007;39:505-528.
2. Ali, S, Hardy, LA, and Kirby, JA. Transplant immunobiology: a crucial role for heparan sulfate glycosaminoglycans? Transplantation. 2003;75:1773-1782.
3. Anastase-Ravion, S, Blondin, C, Cholley, B, Haeffner-Cavaillon, N, Castellot, JJ, and Letourneur, D. Heparin inhibits lipopolysaccharide (LPS) binding to leukocytes and LPS-induced cytokine production. J Biomed Mater Res. 2003;66(2):376-384.
4. Bârzu, T, Molho, P, Tobelem, G, Petitou, M, and Caen, J. Binding and endocytosis of heparin by human endothelial cells in culture. Biochim Biophys Acta. 1985;845:196-203.
5. Bârzu, T, Van Rijn, JL, Petitou, M, Molho, P, Tobelem, G, and Caen, JP. Endothelial binding sites for heparin: specificity and role in heparin neutralization. Biochem J. 1986;238:847-854.
6. Basta, G, Lazzerini, G, Massaro, M, Simoncini, T, Tanganelli, P, Fu, C, Kislinger, T, Stern, DM, Schmidt, AM, De Caterina, R. Advanced glycation end products activate endothelium through signal-transduction receptor RAGE: a mechanism for amplification of inflammatory responses. Circulation. 2002; 105:816-822.
7. Beamish, JA, Geyer, LC, Haq-Siddiqi, NA, Kottke-Marchant, K, and Marchant, RE. The effects of heparin releasing hydrogels on vascular smooth muscle cell phenotype. Biomaterials. 2009;30:6286-6294.
8. Berman, B, Ostrovsky, O, Shlissel, M, Lang, T, Regan, D, Vlodavsky, I, Ishai-Michaeli, R, and Ron, D. Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999;274:36132-36138.
9. Bikfalvi, A, Klein, S, Pintucci, G, and Rifkin, DB. Biological role of fibroblast growth factor-2. Endocr Rev. 1997;18:26-45.
10. Blaukovitch, CI, Pugh, R, Gilotti, AC, Kanyi, D, and Lowe-Krentz, LJ. Heparin treatment of vascular smooth muscle cells results in the synthesis of the dual-specificity phosphatase MKP-1. J Cell Biochem. 2010;May 15;110(2):382-391.
11. Bonecchi, R, Bianchi, G, Bordignon, PP, D'Ambrosio, D, Lang, R, Borsatti, A, Sozzani, S, Allavena, P, Gray, PA, Mantovani, A, and Sinigaglia, F. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187:129-134.
12. Cain, BS, Harken, AH, and Meldrum, DR. Therapeutic strategies to reduce TNFa mediated cardiac contractile depression following ischemia and reperfusion. J Mol Cell Cardiol. 1999;31:931-947.
13. Castellot, JJ, Beeler, DL, Rosenberg, RD, and Karnovsky, MJ. Structural determinants of the capacity of heparin to inhibit the proliferation of vascular smooth muscle cells. J Cell Physiol. 1984;120: 315-320.
14. Castellot, JJ, Wong, K, Herman, B, Hoover, RL, Albertini, DF, Wright, TC, Caleb, BL, and Karnovsky, MJ. Binding and internalization of heparin by vascular smooth muscle cells. J Cell Physiol. 1985;124:13-20.
15. Castellot, JJ, Favreau, LV, Karnovsky, MJ, and Rosenberg, RD. Inhibition of vascular smooth muscle cell growth by endothelial cell-derived heparin. Possible role of a platelet endoglycosidase. J Biol Chem. 1982;257(19):11256-11260.
16. Chen, E, Hermanson, S, and Ekker, SC. Syndecan-2 is essential for angiogenic sprouting during zebrafish development. Blood. 2004;103:1710-1719.
17. Cizmeci-Smith, G, Langan, E, Youkey, J, Showalter, LJ, and Carey, DJ. Syndecan-4 is a primary-response gene induced by fibroblast growth factor and arterial injury in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:172-180.
18. Clarke, D, Katoh, O, Gibbs, RV, Griffiths, SD, and Gordon, MY. Interaction of interleukin 7 (IL-7) with glycosaminoglycans and its biological relevance. Cytokine. 1995;7:325-330.
19. David, G. Integral membrane heparan sulfate proteoglycans. FASEB J. 1993;7:1023-1030.
20. Dickinson, RJ and Keyse, SM. Diverse physiological functions for dual-specificity MAPK kinase phosphatases. J Cell Science. 2006;119:4607-4615.
21. Dhillon, AS, von Kriegsheim, A, Grindlay, J, Koch, W. Phosphatase and feedback regulation of Raf-1 signaling. Cell Cycle. 2007;6:3-7.
22. Fannon, M, Forsten, KE, and Nugent, MA. Potentiation and inhibition of bFGF binding by heparin: A model for regulation of cellular response. Biochemistry. 2000;39:1434-1445.
23. Fannon, M and Nugent, MA. Basic fibroblast growth factor binds its receptors, is internalized, and stimulates DNA synthesis in Balb/c3T3 cells in the absence of heparan sulfate. J Biol Chem. 1996;271:17949-17956.
24. Fasciano, S, Patel, RC, Handy, I, Patel, CV. Regulation of Vascular Smooth Muscle Proliferation by Heparin. J Biol Chem. 2005;289(16):15682-89.
25. Fears, CY, Gladson, CL, and Woods, A. Syndecan-2 is expressed in the microvasculature of gliomas and regulates angiogenic processes in microvascular endothelial cells. J Biol Chem. 2006;281: 14533-14536.
26. Fouty, BW, Grimison, B, Fagan, KA, Le Cras, TD, Harral, JW, Hoedt-Miller, M, Sclafani, RA, and Rodman, DM. p27kip1 Is Important in Modulating Pulmonary Artery Smooth Muscle Cell Proliferation. Am J Respir Cell Mol Biol. 2001;25:652-658.
27. Frostegård, J, Ulfgren, AK, Nyberg, P, Hedin, U, Swedenborg, J, Andersson, U, and Hansson, GK. Cytokine expression in advanced human atherosclerotic plaques: dominance of proinflammatory (Th1) and macrophage-stimulating cytokines. Atherosclerosis. 1999;145:33-34.
28. Fryer, A, Huang, YC, Rao, G, Jacoby, D, Mancilla, E, Whorton, R, Piantadosi, CA, Kennedy, T, and Hoidal, J. Selective O-Desulfation produces nonanticoagulant heparin that retains pharmacological activity in the lung. J Pharmacol Exp Ther. 1997;282:208-219.
29. Fukai, N, Kenagy, RD, Chen, L, Gao, L, Daum, G, and Clowes, AW. Syndecan-1: an inhibitor of artieral smooth muscle cell growth and intimal hyperplasia. Arterioscler Thromb Vasc Biol. 2009;29:1356-1362.
30. Gallagher, JT. Structure-activity relationship of heparan sulfate. Biochemical Soc Trans. 1997; 25:1206-1209.
31. Gandhi, NS and Mancera, RL. The Structure of Glycosaminoglycans and their Interactions with Proteins. Chem Biol Drug Des. 2008;72:455-482.
32. Garg, HG, Mrabat, H, Yu, L, Freeman, C, Li, B, Zhang, F, Linhardt, RJ, and Hales, CA. Significance of the 2-O-sulfo group of the L-iduronic acid residues in heparin on the growth inhibition of bovine pulmonary artery smooth muscle cells. Carbohydr Res. 2008;343:2406-2410.
33. Garner, B, Georgevich, A, Hodgson, AJ, Liu, L, and Wallace, GG. Polypyrrole-heparin composites as stimulus-responsive substrates for endothelial cell growth. J Biomed Mater Res. 1999;44:121-129.
34. Gitay-Goren, H, Soker, S, Vlodavsky, I, and Neufeld, G. The binding of vascular endothelial growth factor to its receptors is dependent on cell surface heparin-like molecules. J Bio Chem. 1992;267:6093-6098.
35. Gengrinovitch, S, Berman, B, David, G, Witte, L, Neufeld, G, and Ron, D. Glypican-1 is a VEGF165 binding proteoglycan that acts as an extracellular chaperone for VEGF165. J Biol Chem. 1999;274(16):10816-10822.
36. Goldin, A, Bechman, JA, Schmidt, AM, Creager, MA. Advanced glycation end products. Sparking the development of diabetic vascular injury. Circulation. 2006;Aug 8;114(6):597-605.
37. Hansson, GK, Libby, P, Schönbeck, U, and Yan, ZQ. Innate and adaptive immunity in the pathogenesis of atherosclerosis. Circ Res. 2002;Aug 23;91(4):281-91.
38. Harmer, NJ. Insights into the role of heparan sulphate in fibroblast growth factor signaling. Biochem Soc Trans. 2006;34:442-445.
39. Hatakeyama, M, Imaizumi, T, Tamo, W, Yamashita, K, Yoshida, H, Fukuda, I, and Satoh, K. Heparin inhibits IFN-induced fractalkine/CX3CL1 expression in human endothelial cells. Inflammation. 2004;28(1):7-13.
40. Horowitz, A, Tkachenko, E, and Simons, M. Fibroblast growth factor-specific modulation of cellular responses by syndecan-4. J Cell Biol. 2002;157(4):715-725.
41. Jalkanen, M, Rapraeger, A, Saunders, S, Bernfield, M. Cell Surface Proteoglycan of Mouse Mammary Epithelial Cells Is Shed by Cleavage of Its Matrix-Binding Ectodomain from Its Membrane-Associated Domain. J Cell Biol. 1987;105:3087-3096.
42. Kato, M, Wang, H, Kainulainen, V, Fitzgerald, ML, Ledbetter, S, Ornitz, DM, and Bernfield, M. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat Med. 1998;4:691-697.
43. Katz, M, Amit, I, and Yarden, Y. Regulation of MAPKs by growth factors and receptor tyrosine kinases. Biochim Biophys Acta. 2007;1773:1161-1176.
44. Kazi, M, Lundmark, K, Religa, P, Gouda, I, Larm, O, Ray, A, Swedenborg, J, and Hedin, U. Inhibition of rat smooth muscle cell adhesion and proliferation by non-anticoagulant heparins. J Cell Physiol. 2002;193:365-372.
45. Kinsella, MG, Tran, PK, Weiser-Evans, MC, Reidy, M, Majack, RA, and Wight, TN. Changes in perlecan expression during vascular injury: role in the inhibition of smooth muscle cell proliferation in the late lesion. Arterioscler Thromb Vasc Biol. 2003;23:608-614.
46. Kojima, T, Takagi, A, Maeda, M, Segawa, T, Shimizu, A, Yamamoto, K, Matsushita, T, and Saito, H. Plasma levels of syndecan-4 (Ryudocan) are elevated in patients with acute myocardial infarction. Thromb Haemost. 2001;85:793-799.
47. Lander, HM, Tauras, JM, Ogiste, JS, Hori, O, Moss, RA, and Schmidt, AM. Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen activated protein kinase pathway regulated by oxidant stress. J Biol Chem. 1997;272:17810-17814.
48. Li, G, Yang, P, Liao, Y, and Huang, N. Tailoring of the titanium surface by immobilization of heparin/fibronectin complexes for improving blood compatibility and endothelialization: an in vitro study. Biomacromolecules. 2011(a);12:1155-1168.
49. Li, G, Yang, P, Qin, W, Maitz, MF, Zhou, S, and Huang, N. The effect of coimmobilizing heparin and fibronectin on titanium on hemocompatibility and endothelialization. Biomatierials. 2011(b);Jul;32(21):4691-703.
50. Lindahl, U, Kusche-Gullberg, M, & Kjellén, L. Regulated diversity of heparan sulfate. J Biol Chem. 1998;273(39):24979-24982.
51. Lortat-Jacob, H, Garrone, P, Banchereau, J, and Grimaud, JA. Human interleukin 4 is a glycosaminogloycan-binding protein. Cytokine. 1997;9:101-105.
52. Lundin, L, Larsson, H, Kreuger, J, Kanda, S, Lindahl, U, Salmivirta, M, and Claesson-Welsh, L. Selectively Desulfated Heparin Inhibits Fibroblast Growth Factor-induced Mitogenicity and Angiogenesis. J Biol Chem. 2000;275:24653-24660.
53. Mach, F, Sauty, A, Iarossi, AS, Sukhova, GK, Neote, K, Libby, P, and Luster, AD. Differential expression of three T lymphocyte-activating CXC chemokines in human atheroma-associated cells. J Clin Invest. 1999;104:1041-1050.
54. Malavaki, CJ, Theocharis, AD, Lamari, FN, Kanakis, I, Tsegenidis, T, Tzanakakis, GN, and Karamanos, NK. Heparan sulfate: biological significance, tools for biochemical analysis and structural characterization. Biomed Chromatogr. 2011;25:11-20.
55. Mamluk, R, Gechtman, Z, Kutcher, ME, Gasiunas, N, Gallagher, J, and Klagsbrun, M. Neuropilin-1 binds vascular endothelial growth factor 165, placenta growth factor-2, and heparin via its b1b2 domain. J Biol Chem. 2002;277:24818-24825.
56. Mann, BK, Gobin, AS, Tsai, AT, Schmedlen, RH, and West, RL. Smooth muscle cells growth in photopolymerized hydrogels with cell adhesive and proteolytically degradable domains: synthetic ECM analogs for tissue engineering. Biomaterials. 2001;22(22):3045-3051.
57. Mishra-Gorur, K and Castellot, JJ. Heparin Rapidly and Selectively Regulates Protein Tyrosine Phosphorylation in Vascular Smooth Muscle Cells. J Cell Physiol. 1999;178:205-215.
58. Mongiat, M, Taylor, K, Otto J, Aho, S, Uitto, J, Whitelock, JM, and Iozzo, RV. The protein core of the proteoglycan perlecan binds specifically to fibroblast growth factor-7. J Biol Chem. 2000;275(10):7095-7100.
59. Mrabat, H, Garg, HG, Hales, CA. Growth inhibition of bovine pulmonary artery smooth muscle cells following long-term heparin treatment. J Cell Physiol. 2009;221:603-608.
60. Multhaupt, HA, Yoneda, A, Whiteford, JR, Oh, ES, Lee, W, and Couchman, JR. Syndecan signaling: when, where, and why? J Physiol Pharmacol. 2009;60(4):31-38.
61. Nikolova, V, Koo, CY, Ibrahim, SA, Wang, Z, Spillmann, D, Dreier, R, Kelsch, R, Fischgräbe, J, Smollich, M, Rossi, LH, Sibrowski, W, Wülfing, P, Kiesel, L, Yip, GW, and Götte, M. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis. 2009;30:397-407.
62. Noguer, O, Villena, J, Lorita, J, Vilaró, S, Reina, M. Syndecan-2 downregulation impairs angiogenesis in human microvascular endothelial cells. Exp Cell Res. 2009;315:795-808.
63. Nugent, MA and Edelman, ER. Kinetics of basic fibroblast growth factor binding to its receptor and heparan sulfate proteoglycans: a mechanism for cooperativity. Biochemistry. 1992;31:8876-8883.
64. Ono, K, Hattori, H, Takeshita, S, Kurita, A, and Ishihara, M. Structural features in heparin that interact with VEGF165 and modulate its biological activity, Glycobiology. 1999;9:705-711.
65. Ottlinger, ME, Pukac, LA, Karnovsky, MJ. Heparin Inhibits Mitogen-Activated Protein Kinase Activation in Intact Rat Vascular Smooth Muscle Cells. J Biol Chem. 1993;268:19173-19761.
66. Patton, WA, Granzow, CA, Getts, LA, Thomas, SC, Zotter, LM, Gunzel, KA, and Lowe-Krentz, LJ. Identification of a heparin-binding protein using monoclonal antibodies that block heparin-binding to porcine aortic endothelial cells. Biochem J. 1995;331:461-469.
67. Penc, SF, Pomahac, B, Eriksson, E, Detmar, M, and Gallo, RL. Dermatan sulfate activates nuclar factor-B and induces endothelial and circulating intercellular adhesion molecule-1. J Clin Invest. 1999;103:1329-1335.
68. Presta, M, Dell'Era, P, Mitola, S, Moroni, E, Ronca, R, and Rusnati, M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev. 2005;16:159-178.
69. Pugh, R. Determining How Heparin Interferes with the MAPK/ERK Pathway: An Attempt to Understand the Atherosclerotic Process. Diss. Lehigh University. 2010.
70. Pukac, LA, Castellot, JJ, Wright, TC, Caleb, BL, Karnovsky, MJ. Heparin Inhibits c-fos and c-myc mRNA Expression in Vascular Smooth Muscle Cells. Cell Regul. 1990;Apr;1(5):435-443.
71. Pukac, LA, Ottlinger, ME, Karnovsky, MJ. Heparin Suppresses Specific Second Messenger Pathways for Proto-oncogene Expression in Rat Vascular Smooth Muscle Cells. J Biol Chem. 1992;267:3707-3711.
72. Pukac, LA, Carter, JE, Ottlinger, ME, Karnovsky, MJ. Mechanisms of Inhibition by Heparin of PDGF Stimulated MAP Kinase Activation in Vascular Smooth Muscle Cells. J Cell Physiol. 1997;122:69-78.
73. Purushothaman, A, Uyama, T, Kobayashi, F, Yamada, S, Sugahara, K, Rapraeger, AC, and Sanderson, RD. Heparanse-enhanced shedding of syndecan-1 by myeloma cells promotes endothelial invasion and agniogenesis. Blood. 2010;115(12):2449-2457.
74. Qiao, D, Meyer, K, Mundhenke, C, Drew, SA, and Friedl, A. Heparan sulfate proteoglycans as regulators of fibroblast growth factor-2 signaling in brain endothelial cells. J Biol Chem. 2003;278(18):16045-16053.
75. Ramsden, L and Rider, CC. Selective and differential binding of interleukin (IL)-1 alpha, IL-1 beta, IL-2 and IL-6 to glycosaminoglycans. Eur J Immunol. 1992;22:3027-3031.
76. Ranjbaran, H, Wang, Y, Manes, TD, Yakimov, AO, Akhtar, S, Kluger, MS, Pober, JS, and Tellides, G. Heparin displaces interferon-inducible chemokines (IP-10, I-TAC, and Mig) sequestered in the vasculature and inhibits the transendothelial migration and arterial recruitment of T cells. Circulation. 2006;114:1293-1300.
77. Rao, NV, Argyle, B, Xu, X, Reynolds, PR, Walenga, JM, Prechel, M, Prestwich, GD, MacArthur, RB, Walters, BB, Hoidal, JR, and Kennedy, TP. Low anticoagulant heparin targets multiple sites of inflammation, suppresses heparin-induced thrombocytopenia, and inhibits interaction of RAGE with its ligands. Am J Cell Physiol. 2010;299:C97-C110.
78. Rauch, BH, Millette, E, Kenagy, RD, Daum, G, Fischer, JW, and Clowes, AW. Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells. J Biol Chem. 2005;280(17):17507-17511.
79. Reilly, CF, Kindy, MS, Brown, KE, Rosenberg, RD, and Sonenshein, GE. Heparin prevents vascular smooth muscle cell progression through the G1 phase of the cell cycle. J Biol Chem. 1989;264(12):6990-6995.
80. Reuss, B and von Bohlen und Halbach, O. Fibroblast growth factors and their receptors in the central nervous system. Cell Tissue Res. 2003;313:139-157.
81. Roberts, R, Gallagher, J, Spooncer, E, Allen, TD, Bloomfield, F, and Dexter, TM. Heparan sulphate bound growth fractors: a mechanism for stromal cell mediated haemopoiesis. Nature. 1988;332:376-378.
82. Rosenberg, RD, Shworak, NW, Liu, J, Schwartz, JJ, and Zhang, L. Heparan sulfate proteoglycans of the cardiovascular system. Specific structures emerge but how is synthesis regulated? J Clin Invest. 1997;99:2062-2070.
83. Salgame, P, Abrams, JS, Clayberger, C, Goldstein, H, Convit, J, Modlin, RL, and Bloom, BR. Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science. 1991;254:279-282.
84. Saunders, S, Jalkanen, M, O'Farrell, S, Bernfield, M. Molecular cloning of syndecan, an integral membrane proteoglycan. J Cell Biol. 1989;108:1547-1556.
85. Savage, JM, Gilotti, AC, Granzow, CA, Molina, F, and Lowe-Krentz, LJ. Antibodies against a heparin receptor slow cell proliferation and decrease MAPK activation in vascular smooth muscle cells. J Cell Physiol. 2001;187:283-293.
86. Segev, A, Nili, N, and Strauss, BH. The role of perlecan in arterial injury and angiogensis. Cardio Res. 2004;63:603-610.
87. Shih, VF, Tsui, R, Caldwell, A, Hoffmann, A. A single NFB system for both canonical and non-canonical signaling. Cell Res. 2011;21:86-102.
88. Spivak-Kroizman, T, Lemmon, MA, Dikic, I, Ladbury, JE, Pinchasi, D, Huang, J, Jaye, M, Crumley, G, Schlessinger, J, and Lax, I. Heparin-induced oligomerization of FGF molecules is responsible for FGF receptor dimerization, activation, and cell proliferation. Cell. 1994;79:1015-1024.
89. Subramanian, SV, Fitzgerald, ML, and Bernfield, M. Regulated shedding of syndecan-1 and -4 ectodomains by thrombin and growth factor receptor activation. J Biol Chem. 1997;272(23):14713-14720.
90. Thourani, VH, Brar, SS, Kennedy, TP, Thornton, LR, Watts, JA, Ronson, RS, Zhao, ZQ, Sturrock, AL, Hoidal, JR, and Vinten-Johansen, J. Nonanticoagulant heparin inhibits NF-kappaB activation and attenuates myocardial reperfusion injury. Am J Physiol Heart Cir Physiol. 2000;48:H2084-H2093.
91. Tran, PK, Tran-Lundmark, K, Soininen, R, Tryggvason, K, Thyberg, J, and Hedin, U. Increased intimal hyperplasia and smooth muscle cell proliferation in transgenic mice with heparan sulfate-deficient perlecan. Circ Res. 2004;94:550-558.
92. Underwood, PA, Mitchell, SM, Whitelock, JM. Heparin fails to inhibit the proliferation of human vascular smooth muscle cells in the presence of human serum. J Vas Res. 1998;35:449-460.
93. Underwood, PA and Mitchell, SM. Low density lipoproteins in human plasma make vascular smooth muscle cells resistant to growth inhibition by heparin. Cardiovasc Res. 2000;Sep;47(4):749-58.
94. Vadiveloo, PK, Filonzi, EL, Stanton, HR, Hamilton, JA. G1 phase arrest of human smooth muscle cells by heparin, IL-4, and cAMP is linked to repression of cyclin D1 and cdk2. Atherosclerosis. 1997;Aug;133(1):61-69.
95. van Besouw, NM, Daane, CR, Vaessen, LM, Mochtar, B, Balk, AH, and Weimar, W. Donor-specific cytokine production by graft-infiltrating lymphocytes induces and maintains graft vascular disease in human cardiac allografts. Transplantation. 1997;63:1313-1318
96. Wang, L, Brown, JR, Varki, A, and Esko, JD. Heparin's anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J Clin Invest. 2001;Jul;110(1):127-136.
97. Webb, LM, Ehrengruber, MU, Clark-Lewis, I, Baggiolini, M, and Rot, A. Binding to heparan sulfate or heparin enhances neutrophil responses to interleukin 8. PNAS. 1993;90:7158-7162.
98. Weiler, JM, Edens, RE, Linhardt, RJ, and Kapelanski, DP. Heparin and modified heparin inhibit complement activation in vivo. J Immunol. 1992;148:3210-3215.
99. Xu, D, Fuster, MM, Lawrence, R, and Esko, JD. Heparan sulfate regulates VEGF165-and VEGF121-mediated vascular hyperpermeability. J Biol Chem. 2011;286(1):737-745.
100. Yu, L, Quinn, DA, Garg, HG, Hales, CA. Gene expression of cyclin-dependent kinase inhibitors and effect of heparin on their expression in mice with hypoxia-induced pulmonary hypertension. Biochem Biophys Res Commun. 2006;345:1565-1572.